May 29, 2020
Eisai Announces Updated Results of ENHANCE 1, a Phase 1b/2 Trial Investigating HALAVEN® (eribulin mesylate) plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Triple-Negative Breast Cancer at ASCO 2020
Mar 19, 2020
Positive Results from Registrational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) in Advanced Endometrial Carcinoma Published in the Journal of Clinical Oncology
Feb 15, 2020
Eisai Announces Latest Data for LENVIMA® (lenvatinib) in Combination with Everolimus for Advanced Non-Clear Cell Renal Cell Carcinoma
Feb 13, 2020
Eisai to Voluntarily Withdraw BELVIQ®/BELVIQ XR® in the U.S.
Feb 10, 2020
Eisai to Present Latest on LENVIMA® (lenvatinib) at the 2020 Genitourinary Cancers Symposium
Jan 21, 2020
Eisai to Present Latest Data on LENVIMA® (lenvatinib) at the 2020 Gastrointestinal Cancers Symposium
Dec 27, 2019
Pivotal Phase 3 Study of DAYVIGO(TM) (lemborexant) for the Treatment of Insomnia Disorder Published in JAMA Network Open
Dec 23, 2019
U.S. FDA Approves Eisai's DAYVIGO(TM) (lemborexant) for the Treatment of Insomnia in Adult Patients
Dec 10, 2019
Eisai Presents New Analyses of Potential Blood-Based Alzheimer's Diagnostic Test and Lemborexant as Potential Sleep-Wake Disorder Therapy
Dec 09, 2019
Eisai Presents New Seizure Freedom and Adherence Data Related to Anti-Epileptic Drug FYCOMPA® at the 2019 American Epilepsy Society Annual Meeting
Dec 09, 2019
Lower Hospitalization Rates Seen Among Epilepsy Patients Treated with FYCOMPA® and Select Anti-Epileptic Drug (AED) Combinations
Dec 02, 2019
Eisai and Biogen's Joint Investigational Asset BAN2401 Data to be Presented at Clinical Trials on Alzheimer's Disease Conference
Nov 25, 2019
Eisai to Present Convulsive Seizure Freedom Data Evaluating FYCOMPA® in Newly Diagnosed Partial Onset Patients at Upcoming American Epilepsy Society Annual Meeting
Sep 27, 2019
Three New Analyses of Data Expand Understanding of the Potential Role for Investigational Agent Lemborexant in Insomnia and Irregular Sleep-Wake Rhythm Disorder
Sep 24, 2019
Eisai Announces Data Presentations on KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Investigational Combination Therapy and HALAVEN® (eribulin) at ESMO 2019
Sep 19, 2019
Eisai to Present New 12-month Safety & Effectiveness Data from Phase 3 Lemborexant SUNRISE 2 Study and New Patient and Cohabitant Insights about Insomnia and Toll on Next-Day Functioning at World Sleep Congress
Sep 13, 2019
Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
Sep 09, 2019
SpePharm AG Wins Case Against Eisai Inc. in United States District Court for District of Delaware
Aug 26, 2019
Priya Chaturvedi, Ph.D., Appointed Vice President of Global Clinical Quality Assurance at Eisai Inc.
Jul 11, 2019
New Data in 2 Oral and 13 Poster Presentations about Eisai's Latest Dementia Pipeline, Including BAN2401, Elenbecestat and Lemborexant, to be Presented at Alzheimer's Association International Conference